Kidney Cancer Clinical Trials Consortium
Abstract
Our emerging understanding of how kidney cancer cells interact with normal tissues in the body has led to the development of new treatments capable of directing the body’s immune response against the tumor, as well as treatments that inhibit the growth of blood vessels that feed the tumor. However, the complexity of each patient’s specific tumor environment requires a tailored approach to increase their overall probability of cure. It also requires the use of novel measurement techniques that determine how effective we are at treating the cancer. This tailored approach is typically not pursued in pharmaceutical company-sponsored clinical trials. For us to develop a new treatment paradigm for patients with advanced or metastatic kidney carcinoma, we need to develop infrastructure that supports clinical studies focused on developing novel strategies, biomarkers, and treatment combinations. These trials will be run at multiple centers of research excellence to permit rapid accrual and to encourage interaction between leaders in the field who are capable of developing the novel tools required to make these trials a success. The Department of Defense Kidney Cancer Research Consortium is set up to create the network required to facilitate implementation of these trials at leading academic centers. The major goal of this grant is to set up the infrastructure required to efficiently perform cutting-edge, biomarker-driven clinical trials. We will achieve this by developing a harmonized clinical trial approval and monitoring process, by applying a flexible and efficient data management platform, by implementing an innovative sample analysis infrastructure, and by engaging pharmaceutical partners, the patient community, and the companies developing biomarker platforms to participate in the Consortium. By creating this new infrastructure we will harness the power of leading research institutions around the country, the patient advocacy community, companies developing biomarker platforms, and the pharmaceutical industry to rapidly advance our ability to bring truly personalized treatment to individuals with advanced or metastatic kidney cancer. This two-year grant will set the stage for running these trials in the Consortium. We anticipate that in the next four to five years the Consortium will begin to deliver novel biomarkers and treatment approaches to the kidney cancer community.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1820052
Entities
People
- Eric Jonasch
Organizations
- United States Army
- University of Texas at Austin